Sign in
TerminatedPhase 2

Effect of Dietary Nitrate Ingestion in Heart Failure

Key facts

Who runs it
Queen Mary University of London
Where
United Kingdom1 site in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
Phase
Phase 2
People taking part
2 people enrolled
Started
1 Jun 2018
Ended
7 Jan 2025
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Nitrate-rich Beetroot Juice
  • Nitrate-deplete Beetroot Juice
Record updated
3 August 2025
Why it stopped
abandoned

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Age ≥18 years
  • Diagnosed with heart failure with reduced ejection fraction on the basis of:; LVEF ≤50% as assessed by Echocardiography (or cardiac MRI); raised BNP and/or NT-proBNP levels placing patients in the "high risk" category, to ensure heart failure is the cause of symptoms:; stable heart failure: NT-proBNP >600pg/mL and BNP >150pg/mL; hospitalisation within 12 months: NT-proBNP >400pg/mL and BNP >100pg/mL
  • NYHA Class II-III symptoms
  • On optimally-tolerated, stable (>12 weeks) prognostic medical therapy (beta-blocker, ACE-inhibitor or ARB, mineralocorticoid therapy if deemed necessary)
  • No heart failure-related hospitalisation for >12 weeks
  • Clinic systolic blood pressure ≥95mmHg
  • Able and willing to give written informed consent; The intervention with dietary nitrate is intentionally designed to be in addition to the patient's own lifestyle. There will be no restrictions placed on diet, anti-oxidant supplements or prescription medications, other than those listed in the exclusion criteria below

Who cannot take part

  • Use of anti-bacterial mouthwash or tongue scrapes (current or unwillingness to cease such mouthcare for at least one month prior to entering the study, and for the duration of the trial) as this interrupts the enterosalivary circuit and thus prevents the bioactivity of nitrate
  • History of recurrent symptomatic gout or current treatment with xanthine oxidase inhibitors for hyperuricaemia
  • Concomitant use of long acting organic nitrates or phosphodiesterase inhibitors (not including on an as required basis)
  • The subject has a three-month prior history of regular alcohol consumption exceeding an average weekly intake of > 28 units (or an average daily intake of greater than 3 units) for males, or an average weekly intake of > 21 units (or an average daily intake of greater than 2 units) for females. 1 unit is equivalent to a half-pint (284mL) of beer/lager; 25mL measure of spirits or 125mL of wine
  • Angina at CCS Class III/IV, requiring regular use of sublingual GTN (considered >twice/week), or awaiting revascularisation
  • History of symptomatic renal stone disease
  • Current life-threatening condition that might prevent a patient-subject completing the study
  • Allergy to SonoVue Echo contrast
  • Subjects with any acute infection, or recent systemic antibiotics (oral or intravenous) within 3 months of screening, or significant trauma (burns, fractures)
  • Mobility thought to be restricted significantly by other illnesses apart from heart failure
  • If LVEF in the range 40-50%, impaires systolic function secondary to uncorrected valve disease, primary pulmonary hypertension, active myocarditis, constrictive pericarditis, restrictive cardiomyopathy or hypertrophic cardiomyopathy
  • Renal failure with eGFR<30 at screening
  • Any other subject whom the Investigator deems unsuitable for the study (e.g. due to other medical reasons, laboratory abnormalities, expected study medication noncompliance, or subject's unwillingness to comply with all study-related study procedures)
  • Pregnancy, breast feeding or planned pregnancy
  • Anaemia, defined as Haemaglobin <80g/L

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study evaluates the addition of inorganic dietary nitrate to the optimal treatment of patients diagnosed with heart failure with reduced ejection fraction. Some vegetables contain large amounts of inorganic nitrate, and research suggests that this nitrate has beneficial effects on the heart and blood vessels. We have shown in lab experiments that nitrate has positive effects on the heart. We wish to test whether dietary nitrate might be useful in halting deterioration and/or improving heart function in patients with heart failure, with a specific focus on a marker of poor outcome in heart failure: high uric acid levels. Half of the patients will receive nitrate-rich beetroot juice, and the other half a nitrate-deplete placebo beetroot juice.

The 2 groups in the trial

  • Nitrate-rich Beetroot JuiceTreatment being tested

    Individuals will receive a once daily dose of dietary nitrate in the form of a beetroot juice concentrate (70mL) containing \~5-6mmol inorganic nitrate (James White Drinks, UK) for 12 +/- 2 weeks. This dose has been chosen due to several reports demonstrating efficacy in patients with cardiovascular disease.

  • Nitrate-deplete Beetroot JuicePlacebo, for comparison

    The placebo control is an identical juice from which the nitrate anion has been removed using a standard anion exchange resin. Visually there is no detectable difference between the juices and previous spectral, ion concentration, sugar levels, ascorbate analysis and taste testing has confirmed no differences in colour and constituents. The process to extract nitrate from the juice is the same technique used to remove inorganic nitrate from general drinking water supplies, and has been approved for use by Ethics Committees. The nitrate-free juice is not considered a drug or medicine, and is classified as a foodstuff.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Investigation of Dietary Nitrate Optimisation by Hyperuricaemia Stratification in Heart Failure
Record updated
3 August 2025